IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.44 USD -1.88% Intraday chart for IGM Biosciences, Inc. -0.10% +25.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000 MT
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM
North American Morning Briefing : Stock Futures -2- DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20 MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : Futures Pause -2- DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11 MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk MT
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization MT
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap DJ
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development MT
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22% CI
IGM Biosciences, Inc. Announces Plans to File IND for IGM-2644 (CD38 x CD3) to Treat Autoimmune Disease CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs DJ
Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $11 From $17, Keeps Buy Rating MT
Stifel Trims IGM Biosciences' Price Target to $25 From $26, Keeps Buy Rating MT
RBC Cuts Price Target on IGM Biosciences to $8 From $11, Keeps Sector Perform, Speculative Risk MT
Wedbush Lowers IGM Biosciences' Price Target to $16 From $19, Keeps Outperform Rating MT
Chart IGM Biosciences, Inc.
More charts
IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The Company has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
10.44 USD
Average target price
21.5 USD
Spread / Average Target
+105.94%
Consensus
  1. Stock
  2. Equities
  3. Stock IGM Biosciences, Inc. - Nasdaq
  4. News IGM Biosciences, Inc.
  5. Baird Adjusts IGM Biosciences' Price Target to $46 From $65, Keeps Outperform Rating